Fidaxomicin May Be Best Choice for C. difficile
Fidaxomicin merits placement ahead of vancomycin and other agents in treatment of Clostridium difficile infections, according to…
C. difficile
-
Fidaxomicin May Be Best Choice for C. difficile
Fidaxomicin merits placement ahead of vancomycin and other agents in treatment of Clostridium difficile infections, according to... -
Early Fecal Transplant Improves Survival after Severe C. Diff Infection
Patients with severe Clostridium difficile infection (CDI) who receive early fecal microbiota transplant (FMT) have improved survival,... -
Experimental Antibody Reduces Risk of C. difficile Recurrence
An experimental antibody developed by Merck & Co Inc. was shown in pivotal studies to reduce by...
Early Fecal Transplant Improves Survival after Severe C. Diff Infection
Patients with severe Clostridium difficile infection (CDI) who receive early fecal microbiota transplant (FMT) have improved survival,…
Experimental Antibody Reduces Risk of C. difficile Recurrence
An experimental antibody developed by Merck & Co Inc. was shown in pivotal studies to reduce by…
New Treatment for Recurrent C. difficile Shows Promise
Giving people harmless spores of Clostridium difficile by mouth proved safe and effective in stopping recurrent bouts…
C. Difficile, Monospot Tests Often Not Effective in Pediatric Patients
As educators, we love—and are always humbled by—those moments when we get to say, “I don’t know.”…